Why did Danaher's revenue decline so sharply in 2023?

The decline was driven primarily by lower demand for COVID-19 related testing, vaccines and therapeutics. COVID-related products contributed roughly 9.5 percentage points of the 10.0% full-year core revenue decline, while base business core revenue fell only 0.5%. Currency and acquisition/divestiture effects were comparatively small.

What does the 2024 guidance imply for investors?

Management expects non-GAAP core revenue to fall high-single digits in Q1 2024 and low-single digits for the full year. This suggests continued near-term pressure, with the decline in the first quarter expected to be steeper than for the year as a whole. The guidance excludes acquisition, divestiture and currency effects and does not include a GAAP revenue forecast.

Is Danaher still generating strong cash flow despite lower earnings?

Yes, but less than before. Operating cash flow from continuing operations was $6.5B for 2023 (down about 15%), and free cash flow was $5.1B (down about 21.5%). Cash generation remains substantial relative to the company's capital expenditures of about $1.4B, although the Abcam acquisition and related investing outflows were significant.

What is the difference between GAAP and adjusted EPS, and why does it matter?

GAAP diluted EPS from continuing operations was $5.65 for 2023, while adjusted EPS was $7.58. The gap largely reflects amortization of acquisition-related intangibles ($2.00 per share), fair value losses on investments ($0.24), and acquisition-related items ($0.13), partly offset by tax effects. Investors should weigh both measures, since the adjusted figure excludes recurring acquisition amortization that will continue in future periods.

Why did Danaher change how it reports revenue metrics?

Beginning in Q1 2024, Danaher will stop guiding to and reporting base business core revenue, because it believes the pandemic has transitioned to an endemic state. As a result, future reporting will rely on total core revenue growth, which means investors will have less visibility into the underlying growth of the non-COVID business going forward.

DHR 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed January 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Danaher's (DHR) Q4 and full-year 2023 results, furnished under Item 2.02, show a year of sharp top-line contraction as COVID-19 demand unwound, with partial offsets from the Abcam acquisition and the Veralto spin-off.

Fourth-quarter revenue fell 10.0% year-over-year to $6.4 billion^a, with non-GAAP core revenue down 11.5% (including a 4.5% base business decline). Full-year revenue declined 10.5% to $23.9 billion, with core revenue down 10.0%. GAAP diluted EPS from continuing operations was $1.50 in Q4 and $5.65 for the year, while non-GAAP adjusted diluted EPS was $2.09 and $7.58, respectively.

Adjusted EPS was down from $2.54^b and $9.71 in the prior-year periods. Operating margin compressed meaningfully, with GAAP operating margin at 20.9% in Q4 versus 28.0% a year earlier, and 21.8% for the full year versus 28.3%. Cash generation remained solid but weaker.

Operating cash flow from continuing operations was $6.5 billion^c for the year (down about 15%), and free cash flow was $5.1 billion (down about 21.5%). Q4 free cash flow fell about 38% to $1.2 billion. The balance sheet expanded substantially, with goodwill rising to $41.6 billion from $37.3 billion and total debt-related liabilities remaining large, as the company completed the Abcam acquisition, which cost roughly $5.6 billion in cash paid for acquisitions in 2023.

Management characterized 2023 as transformational following the Veralto spin-off, positioning Danaher as a more focused Life Sciences and Diagnostics company. Looking ahead, management guided non-GAAP core revenue to decline high-single digits year-over-year in Q1 2024 and low-single digits for full-year 2024.

The company will stop guiding to and reporting base business core revenue, reflecting its view that the pandemic has transitioned to an endemic state. For investors, the key takeaways are the magnitude of the COVID-related revenue unwind, the margin and cash flow pressure, and the near-term guidance, which signals continued softness before any recovery, against the backdrop of a larger, Abcam-enhanced proteomics portfolio.

02—Key points

Key Highlights

Q4 2023 revenue fell 10.0% YoY to $6.4B, with non-GAAP core revenue down 11.5% and base business core revenue down 4.5%.
FY 2023 revenue declined 10.5% to $23.9B; core revenue fell 10.0%, while base business core revenue declined only 0.5%, indicating the decline was driven mainly by COVID-related products.
GAAP diluted EPS from continuing operations was $1.50 in Q4 (vs. $2.70) and $5.65 for FY 2023 (vs. $8.47); non-GAAP adjusted EPS was $2.09 in Q4 (vs. $2.54) and $7.58 for FY (vs. $9.71).
GAAP operating margin compressed to 20.9% in Q4 (from 28.0%) and 21.8% for FY (from 28.3%), with Life Sciences most affected at 12.2% in Q4.
Free cash flow from continuing operations was $5.1B for FY 2023 (down ~21.5%) and $1.2B in Q4 (down ~38%), though operating cash flow of $6.5B remained substantial.
Guidance calls for non-GAAP core revenue to decline high-single digits in Q1 2024 and low-single digits for full-year 2024; Danaher will stop reporting base business core revenue going forward.
The Abcam acquisition closed in 2023 (about $5.6B cash paid for acquisitions), expanding Danaher's proteomics capabilities, and the Veralto spin-off was completed, reshaping the company into a focused Life Sciences and Diagnostics business.

03—Questions

Frequently Asked Questions

Why did Danaher's revenue decline so sharply in 2023?
The decline was driven primarily by lower demand for COVID-19 related testing, vaccines and therapeutics. COVID-related products contributed roughly 9.5 percentage points of the 10.0% full-year core revenue decline, while base business core revenue fell only 0.5%. Currency and acquisition/divestiture effects were comparatively small.
What does the 2024 guidance imply for investors?
Management expects non-GAAP core revenue to fall high-single digits in Q1 2024 and low-single digits for the full year. This suggests continued near-term pressure, with the decline in the first quarter expected to be steeper than for the year as a whole. The guidance excludes acquisition, divestiture and currency effects and does not include a GAAP revenue forecast.
Is Danaher still generating strong cash flow despite lower earnings?
Yes, but less than before. Operating cash flow from continuing operations was $6.5B for 2023 (down about 15%), and free cash flow was $5.1B (down about 21.5%). Cash generation remains substantial relative to the company's capital expenditures of about $1.4B, although the Abcam acquisition and related investing outflows were significant.
What is the difference between GAAP and adjusted EPS, and why does it matter?
GAAP diluted EPS from continuing operations was $5.65 for 2023, while adjusted EPS was $7.58. The gap largely reflects amortization of acquisition-related intangibles ($2.00 per share), fair value losses on investments ($0.24), and acquisition-related items ($0.13), partly offset by tax effects. Investors should weigh both measures, since the adjusted figure excludes recurring acquisition amortization that will continue in future periods.
Why did Danaher change how it reports revenue metrics?
Beginning in Q1 2024, Danaher will stop guiding to and reporting base business core revenue, because it believes the pandemic has transitioned to an endemic state. As a result, future reporting will rely on total core revenue growth, which means investors will have less visibility into the underlying growth of the non-COVID business going forward.

04—Continue

← View all 8-K filings